# Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma

Source: https://onco.cc/key-papers/paper-fu-osteosarcoma-ctdna-eclinicalmedicine-2024/  
OnCo record `paper-fu-osteosarcoma-ctdna-eclinicalmedicine-2024` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

In osteosarcoma, a personalised blood test for leftover cancer after surgery predicted who would relapse, sometimes months before scans.

## Summary

Of 83 patients with osteosarcoma at the First Affiliated Hospital of Sun Yat-sen University, tumour-informed panels from whole-exome sequencing were obtained for 71 (85.5 per cent); 59 had panels and blood samples. Thirteen had ctDNA detected after surgery. Negative postoperative ctDNA was associated with better event-free survival at each time point studied and was a significant predictor in multivariate analysis; ctDNA preceded positive imaging in five patients by an average of 92.6 days.

## Fields

- Kind: Key paper
- Last checked: 2026-11-04
- Journal: eClinicalMedicine
- Year: 2024
- DOI: 10.1016/j.eclinm.2024.102697
- Authors: Fu Y, Xu Y, Liu W, et al.
- Findings: Panels obtained for 85.5% of patients.; 13 of 59 ctDNA-positive after surgery; ctDNA predicted event-free survival.; Lead time over imaging 92.6 days on average in 5 patients.
- What it means: Residual disease blood tests extend to bone sarcoma. The methods state a variant allele frequency limit of 0.01 per cent.
- Caveats: Single centre.

## Sources

- Fu et al., eClinicalMedicine 2024: https://doi.org/10.1016/j.eclinm.2024.102697
- PubMed: https://pubmed.ncbi.nlm.nih.gov/39022798/

## Connected records

- cancers: [Osteosarcoma](https://onco.cc/cancers/osteosarcoma/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- drugs: [OriMIRACLE S](https://onco.cc/drugs/orimiracle-s/)
- companies: [OrigiMed](https://onco.cc/companies/origimed/)
- terms: [Circulating tumour DNA (ctDNA)](https://onco.cc/terms/ctdna/), [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/), [Tumour-informed versus tumour-naive ctDNA assays](https://onco.cc/terms/tumour-informed-assay/)

---
JSON: https://onco.cc/api/v1/entities/paper-fu-osteosarcoma-ctdna-eclinicalmedicine-2024.json